PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a
(PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic
hepatitis C virus (CHC) infection in children.
The purpose of this study is also to determine whether PEG-2a in combination with RV or
PEG-2a alone will result in a longer response rate in children with CHC.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)